SEC Form 4 · accession 0000885590-15-000053
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pavel Mirovsky
Officer — EVP, Pres. & GM Valeant EMENA
Period of report
Jun 23, 2015
Accepted (ET)
Jun 24, 2015 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par valueF1,F2,F3 | Jun 23, 2015 | A | 5,000 | $0.00 | A | 69,525 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This number represents common shares ("Common Shares") of Valeant Pharmaceuticals, Inc. ("Valeant") issued upon vesting of performance-based RSUs ("PSUs").
- F2This number includes the maximum number of Common Shares that may be delivered in settlement of performance-based Restricted Share Units ("PSUs") that were previously reported on Form 4 in Table II. See note (3).
- F3The initial grant of PSUs was reported to vest based on total shareholder return ("TSR") between a price of $54.15 starting on May 15, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on February 15, 2015, 50% May 15, 2015 and 25% on August 15, 2015 (or 25% on February 15, 2016, 50% on May 15, 2016 and 25% on August 15, 2016, if applicable). Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs remain unvested for up to 2,500 Common Shares.